Abstract: The present invention relates to transthyretin (TTR) fusions useful in the dimerization and tetramerization of antibodies and antibody fragments, such as Fabs. The TTR fusions proteins described herein are particularly useful in increasing antibody avidity and in enhancing antigen clustering. Methods for treating diseases using the fusion proteins of the present invention are described herein.
Abstract: The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration.
Abstract: The present invention relates to the use of anti-BAG3 antibodies and its pharmaceutical formulation in the treatment of cardiovascular diseases.
Type:
Grant
Filed:
March 24, 2022
Date of Patent:
March 25, 2025
Assignee:
FIBROSYS S.R.L.
Inventors:
Maria Caterina Turco, Liberato Marzullo, Alessandra Rosati, Margot De Marco, Anna Basile
Abstract: The present invention relates to the field of pulmonary, cardiac and inflammatory disorders. More specifically, the present invention provides methods and compositions for treating disorders associated with Resistin. In a specific embodiment, the present invention provides an antibody that binds human Resistin.
Abstract: The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12 Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.
Type:
Grant
Filed:
April 11, 2022
Date of Patent:
February 25, 2025
Assignee:
Xencor, Inc.
Inventors:
Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Nargess Hassanzadeh-Kiabi, Rumana Rashid
Abstract: The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.
Type:
Grant
Filed:
June 9, 2022
Date of Patent:
February 11, 2025
Assignee:
Ablynx N.V.
Inventors:
Sanjaya Singh, Alisa K. Waterman, Erik Depla, Toon Laeremans, Diane Van Hoorick, Cedric Jozef Néotère Ververken
Abstract: The invention relates to the formulation of pharmaceutical compositions of etanercept. The invention also relates to methods of removing buffer and of formulating pharmaceutical compositions of etanercept.
Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
Type:
Grant
Filed:
June 25, 2021
Date of Patent:
February 4, 2025
Assignees:
Novartis AG, The Trustees of the University of Pennsylvania
Inventors:
Jennifer Brogdon, Eugene Choi, Hilmar Erhard Ebersbach, David Jonathan Glass, Heather Huet, Carl H. June, Joan Mannick, Michael C. Milone, Leon Murphy, Gabriela Plesa, Celeste Richardson, Marco Ruella, Reshma Singh, Yongqiang Wang, Qilong Wu
Abstract: Methods for detecting a prostate cancer in a subject comprise detecting a marker selected from an endosomal associated marker and/or a lysosomal associated marker from the subject.
Type:
Grant
Filed:
January 19, 2022
Date of Patent:
January 28, 2025
Assignee:
UNIVERSITY OF SOUTH AUSTRALIA
Inventors:
Doug Brooks, Emma Parkinson-Lawrence, Ian R. D. Johnson, Lisa Butler
Abstract: The present disclosure generally relates to, inter alia, a class of chimeric switch receptors containing an endodomain of an IL-9 receptor, engineered to modulate transcriptional regulation in a ligand-dependent manner. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating gene expression, modulating an activity of a cell, and/or for the treatment of various health conditions or diseases.
Type:
Grant
Filed:
September 16, 2022
Date of Patent:
January 21, 2025
Assignee:
Parker Institute for Cancer Immunotherapy
Abstract: The present invention relates to heterodimeric Relaxin fusion polypeptides, in particular to heterodimeric Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.
Type:
Grant
Filed:
July 1, 2023
Date of Patent:
January 7, 2025
Assignee:
MEDIMMUNE LIMITED
Inventors:
Isabelle Sermadiras, Monika Anna Papworth, Judy Christiane Paterson, Esther Marie Martin, Peng Ke
Abstract: Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.
Type:
Grant
Filed:
June 10, 2022
Date of Patent:
December 31, 2024
Assignee:
Rutgers, The State University of New Jersey
Inventors:
Renata Pasqualini, Wadih Arap, Fernanda Iamassaki Staquicini, Fortunato Ferrara, Sara D'Angelo, Andrew R. M. Bradbury
Abstract: The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific VH, VL, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.
Type:
Grant
Filed:
March 16, 2021
Date of Patent:
December 10, 2024
Assignee:
H. LUNDBECK A/S
Inventors:
Maria-Cristina Loomis, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren
Abstract: The present disclosure provides an isolated antigen binding protein. The isolated antigen binding protein can specifically bind to properdin. The present disclosure also provides an anti-properdin antibody and a preparation method and an application thereof.
Type:
Grant
Filed:
September 1, 2023
Date of Patent:
December 10, 2024
Assignee:
LINNO PHARMACEUTICALS INC.
Inventors:
Zhaozhong Han, Lingyu Li, Mengfan Peng, Haiyang Li, Jun Luo, Hongya Pan
Abstract: The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).
Type:
Grant
Filed:
January 15, 2021
Date of Patent:
December 3, 2024
Assignee:
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Abstract: Some embodiments of the methods and compositions provided herein relate to chimeric antigen receptors (CARs) that specifically bind to human extracellular domains of the IL-13 alpha 2 (IL13Ra2) receptor, cells containing such CARs, and methods of cell-based immunotherapy targeting cancer cells, such as cells of solid tumors.
Abstract: Inflammation is a prominent feature of ischemia-reperfusion injury (IRI) characterized by leukocyte infiltration and renal tubular injury. However, the signals that initiate these events remain poorly understood. The inventors identify the nuclear alarmin interleukin (IL)-33 as an initiation factor of tissue injury and also as a major amplification factor of the innate immune response triggered by experimental kidney ischemia-reperfusion in mice. In mice lacking IL-33, IRI is reduced, as attested by early decreased tubular cell injury, and by subsequent decreased infiltration of IFN-?/IL-17A-producing neutrophils and preservation of renal functions. These findings led the inventors to propose that endogenous IFN-33 contributes to kidney IRI by promoting iNKT cell recruitment and cytokine production, resulting in neutrophil infiltration and activation at the injury site. Accordingly, the present invention relates to antagonists of IL-33 for use in methods for preventing ischemia reperfusion injury in an organ.
Type:
Grant
Filed:
January 24, 2019
Date of Patent:
November 19, 2024
Assignees:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE POITIERS, UNIVERSITE DE POITIERS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Inventors:
André Herbelin, Jean-Marc Gombert, Maroua Ferhat, Antoine Thierry, Jean-Philippe Girard
Abstract: The invention relates to the field of treatment or prevention of obesity-related disorders, atherosclerosis or a coagulation disorder. In particular, the present invention relates to the use of an activator of IFN? receptor for the treatment or prevention of such disorders or conditions, and corresponding methods of treatment.
Type:
Grant
Filed:
March 16, 2018
Date of Patent:
October 22, 2024
Assignees:
BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS
Abstract: Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.
Type:
Grant
Filed:
June 10, 2022
Date of Patent:
October 1, 2024
Assignee:
Rutgers, The State University of New Jersey
Inventors:
Renata Pasqualini, Wadih Arap, Fernanda Iamassaki Staquicini, Fortunato Ferrara, Sara D'Angelo, Andrew R. M. Bradbury